Xvivo Perfusion ABXVIPF -1.32%91 Days Sales Outstanding is 55.09 as of Mar. 2026, which is 14% below its 10-year median of 64.37. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $41.73 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 809 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 56.49% on this metric.
The historical rank and industry rank for Xvivo Perfusion AB's Days Sales Outstanding or its related term are showing as below:
XVIPF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.8 Med: 64.37 Max: 85.14
Current: 70.84
During the past 13 years, Xvivo Perfusion AB's highest Days Sales Outstanding was 85.14. The lowest was 47.80. And the median was 64.37.
XVIPF's Days Sales Outstanding is ranked worse than 56.49% of 809
companies
in the Medical Devices & Instruments industry
Industry Median: 65.46
vs XVIPF: 70.84
Xvivo Perfusion AB's Days Sales Outstanding
declined
from Mar. 2025 (61.13) to Mar. 2026 (55.09).
Xvivo Perfusion AB (OTCPK:XVIPF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Xvivo Perfusion AB Days Sales Outstanding Related Terms
Xvivo Perfusion AB Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Days Sales Outstanding falls into.
Xvivo Perfusion AB Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Days Sales Outstanding of 55.09 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Xvivo Perfusion AB and its competitors. This is 14% below median its historical median of 64.37. Over the past decade, Xvivo Perfusion AB's Days Sales Outstanding has ranged from 47.80 to 85.14. According to the industry distribution chart, Xvivo Perfusion AB ranks #457 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 56.5%.
Is Xvivo Perfusion AB's Days Sales Outstanding too high?
Xvivo Perfusion AB's current Days Sales Outstanding of 55.09 is 14% below median its 10-year median of 64.37. Over the past 10 years, this metric has ranged from a low of 47.80 to a high of 85.14. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.46. Xvivo Perfusion AB's value of 55.09 is 15.8% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #457 out of 809 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #457 out of 809 companies for Days Sales Outstanding. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Days Sales Outstanding is 65.46. Xvivo Perfusion AB's value of 55.09 is 15.8% below this benchmark. Historically, Xvivo Perfusion AB's own Days Sales Outstanding has ranged from 47.80 to 85.14 over the past decade. While the company's 10-year median is 64.37 vs. the industry median of 65.46, Xvivo Perfusion AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.46, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Days Sales Outstanding of 55.09 is 15.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Days Sales Outstanding is 55.09, which is 14% below median its own 10-year median of 64.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.73, compared to a current price of $29.00 — trading 30.5% below its estimated fair value. The current Days Sales Outstanding is 55.09, which is 14% below median its 10-year median of 64.37 and 15.8% below the Medical Devices & Instruments industry median of 65.46. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Days Sales Outstanding is 55.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 30.5% below its estimated GF Value™ of $41.73.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Days Sales Outstanding: 55.09 (14% below median its 10-year median of 64.37)
GF Value™: $41.73 vs. price of $29.00 (30.5% below fair value)
Industry Position: 15.8% below the Medical Devices & Instruments median (#457 of 809)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
